Recent News

• 05.07.2025 - Rhythm Pharmaceuticals 1Q 2025 Earnings Conference Call
• 04.23.2025 - Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
• 04.23.2025 - Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
• 04.07.2025 - Rhythm Pharmaceuticals Conference Call
• 04.07.2025 - Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
• 04.07.2025 - Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
• 04.06.2025 - Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
• 04.06.2025 - Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
• 03.20.2025 - Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
• 03.20.2025 - Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Recent Filings

• 04.18.2025 - PRE 14A Other preliminary proxy statements
• 04.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2025 - 144 Report of proposed sale of securities
• 04.08.2025 - 144 Report of proposed sale of securities
• 04.07.2025 - EX-99.1 EX-99.1
• 04.07.2025 - 8-K Current report
• 03.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - EX-99.1 EX-99.1